Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Rhea-AI Summary

Medivir AB plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks. The data update will be part of Medivir's interim report for the third quarter on Friday, October 27, 2023, followed by a comprehensive update in a webcasted presentation at 14.00 CET the same day.

Positive

• Medivir's data update could increase the opportunity for fostrox + Lenvima® to transform treatment of second line HCC, potentially leading to a faster path to approval and commercial opportunity.

Negative

• None.

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET

STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks. 

The data update will be part of Medivir's interim report for the third quarter on Friday, October 27, 2023, followed by a comprehensive update in a webcasted presentation with associated slide presentation at 14.00 CET the same day.

In the webcast, Medivir will provide further context about how these data increase the opportunity for fostrox + Lenvima® to transform treatment of second line HCC, a population for whom there are no approved medical treatments post current standard of care. In addition, the company will outline how promising clinical benefit in a high unmet medical need second line HCC population, opens the possibility for a faster path to approval and its commercial opportunity.

The webcast will be hosted by Medivir's CEO Jens Lindberg together with Magnus Christensen, CFO, Dr. Pia Baumann, CMO, and Fredrik Öberg, CSO, who are joined in the presentation by Dr. Jeff Evans, who is an investigator in the fostrox clinical development program and a member of Medivir's Scientific Advisory Council. All presenters will be available to answer questions following the formal presentations.

To access the webcast and information about the teleconference, please click HERE!

The webcast will also be streamed via a link on the website: www.medivir.com/investors/calendar

The presentation will be available on Medivir's website after the webcast.

For additional information, please contact;

Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com 

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

The following files are available for download:

https://mb.cision.com/Main/652/3861096/2383608.pdf

Press release (PDF)

 

 

View original content:https://www.prnewswire.com/news-releases/medivir-to-report-new-and-updated-data-from-ongoing-phase-2a-hcc-study-as-part-of-its-q3-report-on-friday-301966908.html

SOURCE Medivir

FAQ

What is Medivir AB planning to report?

Medivir AB plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC).

When will Medivir AB provide the data update?

The data update will be part of Medivir's interim report for the third quarter on Friday, October 27, 2023, followed by a webcasted presentation at 14.00 CET the same day.

What could be the impact of the data update?

The data update could increase the opportunity for fostrox + Lenvima® to transform treatment of second line HCC, potentially leading to a faster path to approval and commercial opportunity.